Nerdwallet Inc vs Revolution Medicines Inc. Common Stock — how do they compare? Nerdwallet Inc trades at $9.84 (market cap $625.17M), while Revolution Medicines Inc. Common Stock trades at $192.57 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 64.5× Nerdwallet Inc's market cap, and Revolution Medicines Inc. Common Stock is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| NRDS | RVMD | |
|---|---|---|
Market Cap | $625.17M | $40.32B |
Volume | 1,321,316 | 4,855,734 |
Sector | Media | Health |
52-Week High | $15.93 | $221.15 |
52-Week Low | $7.58 | $47.50 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $539.47M | $37.02B |
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $10.03, up 10.4% in the last session, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with improving fundamentals - revenue grew from $539M in 2022 to $837M in 2025, with net income turning positive since 2024. Recent news highlights the company's Financial Resilience Index publications and Q2 2026 results showing 6% revenue growth despite search pressure in some product categories.
The outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and projecting 27.9% upside potential. Key risks include organic search volatility and competitive pressures, but strong cash flow generation and attractive valuation multiples (P/E 10.87, P/S 0.81) support the bullish case for long-term investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →